Breaking News Instant updates and real-time market news.

RPD

Rapid7

$35.35

0.33 (0.94%)

, FSCT

ForeScout

$26.83

-0.41 (-1.51%)

11:25
01/09/19
01/09
11:25
01/09/19
11:25

FBN Securities tech/software analysts to hold group luncheon

Technology & Internet Analyst Seyrafi holds a Group Luncheon with Mike Wallace, Senior Sales Engineer at Optive Security, a key security reseller of end-to-end cyber security solutions, in New York on January 9 at 12 pm hosted by FBN Securities.

RPD

Rapid7

$35.35

0.33 (0.94%)

FSCT

ForeScout

$26.83

-0.41 (-1.51%)

CBLK

Carbon Black

$14.07

0.03 (0.21%)

VRNS

Varonis

$54.70

0.03 (0.05%)

CYBR

CyberArk

$77.06

-0.64 (-0.82%)

SAIL

SailPoint

$25.63

0.11 (0.43%)

MIME

Mimecast

$34.54

-0.3 (-0.86%)

QLYS

Qualys

$77.98

1.3 (1.70%)

OKTA

Okta

$68.87

0.12 (0.17%)

SPLK

Splunk

$115.48

0.38 (0.33%)

FEYE

FireEye

$16.90

0.3 (1.81%)

SYMC

Symantec

$19.66

0.09 (0.46%)

ZS

Zscaler

$44.32

0.32 (0.73%)

PFPT

Proofpoint

$90.28

1.11 (1.24%)

PANW

Palo Alto Networks

$194.08

3.68 (1.93%)

  • 09

    Jan

  • 10

    Jan

  • 14

    Jan

  • 15

    Jan

  • 15

    Jan

  • 16

    Jan

  • 16

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 25

    Jan

  • 31

    Jan

  • 06

    Feb

  • 07

    Feb

  • 14

    Feb

  • 21

    Feb

  • 25

    Feb

  • 04

    Mar

RPD Rapid7
$35.35

0.33 (0.94%)

11/29/18
BREN
11/29/18
INITIATION
Target $41
BREN
Buy
Rapid7 initiated with a Buy at Berenberg
Berenberg analyst Alexander Frankiewicz started Rapid7 with a Buy rating and $41 price target.
04/13/18
BTIG
04/13/18
INITIATION
Target $34
BTIG
Buy
Rapid7 initiated with a Buy at BTIG
BTIG analyst Joel Fishbein initiated Rapid7 with a Buy and $34 price target telling investors it has successfully evolved to an end to end provider of security and IT analytics and automation solutions fro SecOps from a niche vulnerability management vendor. Fishbein said the transition to a subscription model provides investors with visibility into profitability next year, reducing a major overhang.
05/09/18
KEYB
05/09/18
NO CHANGE
Target $35
KEYB
Overweight
Rapid7 price target raised to $35 from $30 at KeyBanc
KeyBanc analyst Rob Owens raised his price target for Rapid7 to $35 from $30, citing "strong" Q1 results, supported by accelerating ARR growth to 38% and raised revenue guidance. The analyst reiterates an Overweight rating on the shares.
06/18/18
BTIG
06/18/18
DOWNGRADE
BTIG
Neutral
Rapid7 downgraded to Neutral from Buy at BTIG
BTIG analyst Joel Fishbein downgraded Rapid7 to Neutral from Buy, saying the valuation on the stock has become less compelling at an enterprise value to expected FY20 free cash flow multiple of 28-times. The analyst notes that he is still positive on the company's transformation into a "comprehensive platform for security, IT analytics and SecOps automation solutions" as well as its transition to a subscription based revenue model, but adds that further increases in the stock price would require Rapid7 to exceed its 2020 targets.
FSCT ForeScout
$26.83

-0.41 (-1.51%)

11/29/18
BREN
11/29/18
INITIATION
Target $41
BREN
Buy
ForeScout initiated with a Buy at Berenberg
Berenberg analyst Alexander Frankiewicz started ForeScout Technologies with a Buy rating and $41 price target.
12/13/18
12/13/18
UPGRADE
Target $36

Overweight
ForeScout upgraded to Overweight on ramping growth at Morgan Stanley
As previously reported, Morgan Stanley analyst Melissa Franchi upgraded ForeScout to Overweight from Equal Weight, stating that the pullback in the stock in the past 3 months creates a compelling entry point for a company uniquely exposed to the strong secular themes of enterprises' need to increase security and compliance for a growing diversity of connected devices. Franchi, who sees several drivers of ramping growth for ForeScout in FY19, raised her FY19 revenue growth estimate up to 23% and increased her price target on the stock to $36 from $34.
10/18/18
BARD
10/18/18
INITIATION
Target $42
BARD
Outperform
ForeScout initiated with an Outperform at Baird
Baird analyst Jonathan Ruykhaver last night initiated coverage of ForeScout Technologies with an Outperform rating and $42 price target. The analyst thinks the market could assign a "strategic" multiple to shares above a perpetual license peer group.
12/13/18
MSCO
12/13/18
UPGRADE
MSCO
Overweight
ForeScout upgraded to Overweight from Equal Weight at Morgan Stanley
CBLK Carbon Black
$14.07

0.03 (0.21%)

05/29/18
COWN
05/29/18
INITIATION
Target $29
COWN
Outperform
Carbon Black initiated with an Outperform at Cowen
Cowen analyst Gregg Moskowitz initiated Carbon Black with an Outperform rating as he believes it is one of the few next generation endpoint security companies that are poised to disrupt legacy AV vendors. He cited its unique approach to protection and response and the company's positioning to capitalize on cloud adoption. Moskowitz has a $29 price target on Carbon Black shares.
05/29/18
05/29/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Unity Biotechnology (UBX) initiated with a Buy at Citi, an Overweight at Morgan Stanley, and a Neutral at Goldman Sachs. 2. Construction Partners (ROAD) initiated with an Outperform at Baird, a Strong Buy at Raymond James, an Overweight at Stephens, and a Buy at DA Davidson. 3. Carbon Black (CBLK) initiated with an Outperform at Cowen and William Blair, an Overweight at KeyBanc and JPMorgan, as well as an Equal Weight at Morgan Stanley. 4. Axon (AAXN) initiated with an Outperform at William Blair. 5. Spotify (SPOT) initiated with a Buy at Pivotal Research. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/13/18
SUSQ
07/13/18
INITIATION
Target $27
SUSQ
Neutral
Carbon Black initiated with a Neutral at Susquehanna
Susquehanna analyst Anne Meisner initiated Carbon Black with a Neutral and $27 price target.
10/29/18
JPMS
10/29/18
NO CHANGE
JPMS
JPMorgan lists potential Software takeover targets after Red Hat deal
The volume of acquisitions in Software appears to be picking up with over 70 transactions announced year-to-date including last night's Red Hat (RHT) takeover by IBM (IBM), JPMorgan analyst Sterling Auty tells investors in a research note. The analyst puts the deals announced this year into three buckets: strategic, where the acquirer looks to gain a strong foothold in a new segment, vertical acquiring companies, and valuation, with acquirers going after assets with discounted valuations. Auty sees number of companies fitting those same characteristics across his coverage universe. In the strategic category, the analyst sees Okta (OKTA), Palo Alto Networks (PANW), ServiceNow (NOW), RingCentral (RNG), Aspen Technology (AZPN) and DocuSign (DOCU) as potential acquisition targets. In the vertical industry exposure category, Auty lists Guidewire (GWRE), Veeva (VEEV), Medidata (MDSO), Ellie Mae (ELLI) and Q2 Holdings (QTWO) as potential targets. And in the attractive valuation bucket, the analyst sees FireEye (FEYE), Carbon Black (CBLK), Secureworks (SCWX), Akamai (AKAM) and LogMeln (LOGM) as potential candidates to get acquired.
VRNS Varonis
$54.70

0.03 (0.05%)

10/18/18
WEDB
10/18/18
INITIATION
WEDB
Neutral
Varonis initiated with a Neutral at Wedbush
01/03/19
BNCH
01/03/19
NO CHANGE
BNCH
Activision, Canopy Growth among Best Ideas for first half of 2019 at Benchmark
Benchmark analysts selected their Best Ideas for the first half of 2019, naming 16 stocks, including: Activision Blizzard (ATVI), BioTelemetry (BEAT), Biofrontera (BFRA), Ctrip (CTRP), Huazhu Group (HTHT), II-VI (IIVI), Intevac (IVAC), LHC Group (LHCG), Meredith (MDP), Marvell (MRVL), NeoGenomics (NEO), Pegasystems (PEGA), Silicon Labs (SLAB), Varonis (VRNS), Canopy Growth (CGC) and Waitr Holdings (WTRH).
10/18/18
BARD
10/18/18
INITIATION
BARD
Outperform
Varonis initiated with an Outperform at Baird
Baird analyst Jonathan Ruykhaver last night initiated coverage of Varonis Systems with an Outperform rating and $75 price target. The company deserves a premium valuation compared to perpetual license/maintenance peers due to its "consistency of execution, lack of direct competition, and business value being delivered to customers," Ruykhaver tells investors in a research note.
10/19/18
WEDB
10/19/18
INITIATION
Target $65
WEDB
Neutral
Varonis initiated with a Neutral at Wedbush
Wedbush analyst Daniel Ives initiated Varonis with a Neutral rating and $65 price target, telling investors that while he is positive on the company's product solution and market opportunity over the coming years, the lingering execution issues from the West Coast from Q2 could take another quarter or two to fully fix, although this could be neutralized by a better-than-expected performance on the federal front in Q3.
CYBR CyberArk
$77.06

-0.64 (-0.82%)

12/20/18
DBAB
12/20/18
UPGRADE
DBAB
Buy
CyberArk upgraded to Buy from Hold at Deutsche Bank
12/20/18
DBAB
12/20/18
UPGRADE
Target $85
DBAB
Buy
Deutsche Bank upgrades CyberArk to Buy after channel checks
Deutsche Bank analyst Gray Powell upgraded CyberArk to Buy from Hold with an unchanged price target of $85. The analyst says his firm's recently conducted channel checks on the identity and privilege account-management space came back "with a number of positive data points" for CyberArk. The company's primary competitors are dealing with some form of acquisition-related distraction that should create incremental share gain opportunities for CyberArk over the next year, Powell tells investors in a research note. The analyst sees a "compelling" risk/reward at current share levels and has a high degree of confidence in forecasts for the company next year.
12/21/18
12/21/18
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nike (NKE) upgraded to Overweight from Neutral at JPMorgan and to Buy from Hold at Pivotal Research. 2. CyberArk (CYBR) upgraded to Buy from Hold at Deutsche Bank with analyst Gray Powell saying his firm's recently conducted channel checks on the identity and privilege account-management space came back "with a number of positive data points" for CyberArk. 3. EnerSys (ENS) upgraded to Outperform from Market Perform at William Blair with analyst Brian Drab saying the current valuation, with shares trading at 11 times forward earnings, is attractive. 4. Shopify (SHOP) upgraded to Buy from Neutral at DA Davidson with analyst Tom Forte saying he has long held a very favorable view of the company, particularly founder and CEO Tobi Lutke, but previously felt the share price had accurately reflected his favorable view. 5. OMA Airports (OMAB) upgraded to Buy from Underperform at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/04/19
GSCO
01/04/19
DOWNGRADE
Target $78
GSCO
Neutral
CyberArk downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Gabriela Borges downgraded CyberArk to Neutral and lowered his price target for the shares to $78 from $86. The analyst views the stock's risk/reward as more balanced into 2019. Year-over-year license growth comparisons are more difficult, and Street estimates imply acceleration in license growth on a two-year annual basis, Borges tells investors in a research note. This compares to her industry conversations "which suggest steadier demand." However, the analyst continues to view CyberArk "as a high quality small cap asset."
SAIL SailPoint
$25.63

0.11 (0.43%)

11/08/18
JEFF
11/08/18
NO CHANGE
Target $34
JEFF
Buy
SailPoint earnings selloff a buying opportunity, says Jefferies
In a post-earnings research note titled "An Opportunity," Jefferies analyst John DiFucci says Sailpoint Technologies is trading down 6% following last night's "very strong" Q3 results on weaker than expected Q4 guidance. This was due to the Federal business being pulled into Q3, the analyst says. "Underlying all this is a very strong business," writes DiFucci. He keeps a Buy rating on SailPoint with a $34 price target and sees an opportunity in today's selloff.
11/12/18
GSCO
11/12/18
UPGRADE
Target $33
GSCO
Buy
SailPoint upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Gabriela Borges upgraded SailPoint to Buy and raised her price target to $33 from $32.
11/13/18
11/13/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Veritone (VERI) upgraded to Neutral from Sell at B. Riley FBR with analyst Sameet Sinha citing the company's better than expected Q3 results and increased business visibility for the upgrade to Neutral. 2. Nvidia (NVDA) upgraded to Positive from Neutral at Susquehanna while Xilinx (XLNX) was upgraded to Positive from Neutral. 3. Koppers Holdings (KOP) upgraded to Buy from Neutral at Monness Crespi. 4. Southwestern Energy (SWN) upgraded to Neutral from Underperform at BofA/Merrill with analyst Doug Leggate saying U.S. natural gas prices have lifted by 50c in the past 3 weeks and $1 since September as cold weather forecasts have been updated. 5. SailPoint (SAIL) upgraded to Buy from Neutral at Goldman Sachs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/02/19
MONN
01/02/19
INITIATION
Target $30
MONN
Buy
SailPoint initiated with a Buy at Monness Crespi
Monness Crespi initiated SailPoint with a Buy and $30 price target.
MIME Mimecast
$34.54

-0.3 (-0.86%)

12/06/18
WEDB
12/06/18
INITIATION
WEDB
Neutral
Mimecast initiated with a Neutral at Wedbush
10/29/18
SRCH
10/29/18
DOWNGRADE
SRCH
Hold
Mimecast downgraded to Hold from Buy at Summit Insights
12/07/18
WEDB
12/07/18
INITIATION
Target $40
WEDB
Neutral
Mimecast initiated with a Neutral at Wedbush
Wedbush analyst Steve Koenig initiated Mimecast (MIME) with a Neutral rating and $40 price target. Koenig tells investors in a research note that checks have consistently pointed to superior efficacy with Mimecast vs. Microsoft (MSFT), but Microsoft's bundling of email security with O365 creates some risk in the SMB market. Additionally, the analyst says he is "cautious" on future revenue beats and guidance increases, as Mimecast's TTP product has now penetrated over 60% of its email customer base and upsell potential becomes more limited. While Koening says nothing is "alarming" with Mimecast's fundamentals, shares could have "difficulty" while investors adjust their expectations for continued outperformance.
12/20/18
JEFF
12/20/18
NO CHANGE
JEFF
Jefferies sees 'strong' Software fundamentals heading into 2019
Secular forces in the Software space "remain very strong," and while there are real macro and valuation concerns, indications are that information technology spending trends "will remain supportive in key markets," Jefferies analyst John DiFucci tells investors in a research note titled ": 2019 Outlook: Strong Fundamentals More Than Offset Real Concerns." He believes increased regulation in Europe as well as increased U.S. corporate discretionary capital, along with a setup for continued M&A momentum, "should be supportive of valuations over time." The analyst's top Software picks going into 2019 are Oracle (ORCL), Salesforce (CRM), ServiceNow (NOW), Nice Systems (NICE), Zendesk (ZEN) and Mimecast (MIME).
QLYS Qualys
$77.98

1.3 (1.70%)

11/29/18
BREN
11/29/18
INITIATION
Target $96
BREN
Buy
Qualys initiated with a Buy at Berenberg
Berenberg analyst Alexander Frankiewicz started Qualys with a Buy rating and $96 price target.
11/20/18
BTIG
11/20/18
UPGRADE
Target $100
BTIG
Buy
Qualys upgraded to Buy from Neutral at BTIG
BTIG analyst Joel Fishbein upgraded Qualys to Buy from Neutral with a price target of $100, citing the company's exposure to "secular tailwinds" around the growth of Internet of Things technology and heightened awareness of cyber security risk. The analyst adds that his discussions with customers and partners at QSC 2018 supported the company's "strengthening case that it will be one of the cloud platforms to survive and thrive in the security ecosystem over the next decade". Fishbein is also positive on Qualy's highly attractive profitable growth model and its excellence in R&D development in India.
01/04/19
JMPS
01/04/19
UPGRADE
JMPS
Outperform
Qualys upgraded to Outperform from Market Perform at JMP Securities
01/04/19
JMPS
01/04/19
UPGRADE
Target $85
JMPS
Outperform
JMP Securities upgrades Qualys to Outperform following pullback
As previously reported, JMP Securities analyst Erik Suppiger upgraded Qualys to Outperform from Market Perform as he views the recent pullback as an attractive buying opportunity. He notes Qualys has made significant investments to expand its product portfolio and sees new products being a catalyst in FY19 and FY20, Suppiger tells investors. He also believes the demand environment for Qualys' core VM solution is healthy and will remain a growth driver. Suppiger set a an $85 price target on Qualys shares.
OKTA Okta
$68.87

0.12 (0.17%)

12/10/18
DBAB
12/10/18
NO CHANGE
DBAB
Buy
Okta well on-track to grow revenue over 50% in FY19, says Deutsche Bank
Deutsche Bank analyst Gray Powell reiterates a Buy rating on Okta after meeting with Alex Salazar, the company's VP of Product Strategy and Catherine Buan, head of investor relations. The analyst says the insights he picked up on demand trends were "positive on multiple fronts" and that he came away with a "high degree of confidence" in the company's drivers of long-term growth. Okta is well on-track to grow revenue in excess of 50% in fiscal 2019, Powell tells investors in a research note. Further, he feels "very confident" in the company's forecasts for fiscal 2020 that call for growth of 30%-33% year-over-year.
12/10/18
GUGG
12/10/18
INITIATION
Target $79
GUGG
Buy
Okta initiated with a Buy at Guggenheim
Guggenheim analyst Imtiaz Koujalgi started Okta with a Buy rating and $79 price target. The analyst also added the shares to Guggenheim's Best Idea List.
12/18/18
DADA
12/18/18
INITIATION
Target $62
DADA
Neutral
Okta initiated with a Neutral at DA Davidson
DA Davidson analyst Rishi Jaluria initiated Okta with a Neutral rating and a price target of $62. The analyst is positive on the "value proposition" of the company, along with its "market leadership position and rapid growth", but believes that its stock price is "fully valued" at 12-times enterprise value to expected 2020 revenue. Jaluria adds that he awaits a "better entry point" before becoming more constructive on Okta stock.
12/19/18
12/19/18
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ulta Beauty (ULTA) initiated with a Buy at Citi. 2. Match Group (MTCH) initiated with a Hold at SunTrust. 3. ShotSpotter (SSTI) initiated with an Outperform at Baird. 4. Okta (OKTA) initiated with a Neutral at DA Davidson. 5. Cellectis (CLLS) initiated with a Neutral at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
SPLK Splunk
$115.48

0.38 (0.33%)

12/11/18
12/11/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Neutral from Overweight at JPMorgan with analyst Christopher Schott citing valuation. 2. Splunk (SPLK) resumed with a Neutral from Buy at Guggenheim with analyst Imtiaz Koujalgi saying while the company's fundamentals are strong, he's "looking for more clarity." 3. CalAmp (CAMP) downgraded to Outperform from Strong Buy at First Analysis and to Market Perform from Outperform at Northland. 4. Acorda Therapeutics (ACOR) downgraded to Sell from Neutral at Goldman Sachs with analyst Salveen Richter saying the commercial outlook for Inbrija appears limited. 5. Versum Materials (VSM) downgraded to Sell from Neutral at Goldman Sachs with analyst Toshiya Hari saying while he remains constructive on the Semiconductor Materials sub-sector broadly, he believes the market is underestimating the extent to which weaker semiconductor capital expenditures could negatively impact the Delivery Systems and Services segment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/10/18
GUGG
12/10/18
DOWNGRADE
Target $117
GUGG
Neutral
Splunk resumed with a Neutral from Buy at Guggenheim
Guggenheim analyst Imtiaz Koujalgi resumed coverage of Splunk with a Neutral rating and $117 price target. The rating is a downgrade from the firm's prior coverage of Buy. Guggenheim suspended coverage of Splunk in April of this year. Koujalgi says that while the company's fundamentals are strong, he's "looking for more clarity."
11/30/18
PIPR
11/30/18
NO CHANGE
Target $130
PIPR
Overweight
Splunk price target raised to $130 from $120 at Piper Jaffray
Piper Jaffray analyst Alex Zukin raised his price target for Splunk to $130 and reiterates an Overweight rating on the shares. The analyst says the company last night posted the quarter he was were looking for, with its largest quarterly revenue beat in five years coupled with guidance that outperformed both in the current year and for fiscal 2020. Splunk's fundamentals continue to improve and it remains a "strategic asset trading at a discounted valuation," Zukin tells investors in a post-earnings research note titled "F3Q19 Earnings: Doug E. Fresh With the Beat as King Conte Drops the Mic."
11/30/18
JEFF
11/30/18
NO CHANGE
Target $137
JEFF
Buy
Splunk raised guidance by more than the Q3 beat, says Jefferies
Splunk exceeded fiscal Q3 expectations, raised fiscal 2019 by more than the beat, and raised its outlook for fiscal 2020, Jefferies analyst John DiFucci tells investors in a post-earnings research note. The analyst continues to view the company as a "unique asset" that represents one of the best ways to play the Big Data theme. Further, he believes the underlying business is likely stronger than it appears. The analyst keeps a Buy rating on Splunk with a $137 price target.
FEYE FireEye
$16.90

0.3 (1.81%)

10/31/18
BARD
10/31/18
NO CHANGE
Target $23
BARD
Outperform
FireEye should be bought on strength, says Baird
Baird analyst Jonathan Ruykhaver said the bull narrative for FireEye was hardened following its Q3 results. He said he remains a buyer on the company's recent strength as he believes in management's long-term product strategy and exposure across computing landscapes. Ruykhaver reiterated his Outperform rating and raised his price target to $23 from $22 on FireEye shares.
12/13/18
MSCO
12/13/18
DOWNGRADE
MSCO
Equal Weight
FireEye downgraded to Equal Weight from Overweight at Morgan Stanley
12/13/18
12/13/18
DOWNGRADE
Target $21

Equal Weight
FireEye downgraded to Equal Weight following outperformance at Morgan Stanley
As previously reported, Morgan Stanley analyst Melissa Franchi downgraded FireEye to Equal Weight from Overweight citing the stock's recent relative outperformance with the shares up 20% in the past three months versus the average software name being down 9%. While the outperformance fairly reflects the company's improved product positioning, and Franchi sees a favorable set-up for low teens growth in FY19, she also thinks the set-up may be more challenging looking into FY20 and beyond. She maintains a $21 price target on FireEye shares.
12/13/18
12/13/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Coca-Cola (KO) assumed with a Neutral from Buy at UBS with analyst Sean King saying he sees "moving parts" but says this is "not a new Coke." 2. FireEye (FEYE) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Melissa Franchi citing the stock's recent relative outperformance with the shares up 20% in the past three months versus the average software name being down 9%. 3. Sabre (SABR) downgraded to Hold from Buy at Deutsche Bank with analyst Ashish Sabadra saying he expects the company's global distribution system growth to moderate in 2019. 4. Weatherford (WFT) downgraded to Underperform from Market Perform at Raymond James with analyst J. Marshall Adkins saying he expects Weatherford's upcoming maturity "wall" to push into restructuring and result in an extreme cost to the company's restructured interest payments. 5. Argo Group (ARGO) downgraded to Market Perform from Outperform at Keefe Bruyette. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SYMC Symantec
$19.66

0.09 (0.46%)

11/06/18
LEHM
11/06/18
NO CHANGE
LEHM
Equal Weight
Symantec worth $30-$35 in deal if given Barracuda multiple, says Barclays
If given a similar multiple to Barracuda, which was bought for 20 times current year cash flow, Symantec would be worth $30 to $35 per share in a buyout, Barclays analyst Saket Kalia tells investors in a research note. The analyst points out that Thoma Bravo, which Reuters reported today has approached Symantec to express interest in a potential takeover, acquired Blue Coat in 2012, taking it private until 2015 when it sold the business to Symantec. As such, the private equity firm has been active in security, Kalia adds. He has an Equity Weight rating on Symantec. The stock in midday trading is p 14%, or $2.80, to $22.82.
11/06/18
WEDB
11/06/18
NO CHANGE
WEDB
Symantec shares could be worth $26-$30 in buyout, says Wedbush
After Reuters reported that private equity firm Thoma Bravo has approached Symantec to express interest in a potential takeover, Wedbush analyst Daniel Ives says the company could be worth $26-$30 in a buyout deal. The stock in midday trading is up 14%, or $2.79, to $22.81. The analyst, who has a Neutral rating on Symantec, expects M&A activity in cybersecurity to accelerate in the next 12 to 18 months.
10/19/18
WEDB
10/19/18
INITIATION
Target $19
WEDB
Neutral
Symantec initiated with a Neutral at Wedbush
Wedbush analyst Daniel Ives initiated Symantec with a Neutral rating and $19 price target, telling investors that while Symantec fundamentally still has a core enterprise security customer base and product franchise which has clear value and growth potential, he believes more pain is still ahead as FY19/FY20 Street numbers appear somewhat aggressive with his checks indicating integration issues and longer sales cycles are getting worse and not better in the field. In the near-term the uncertainty from the investigation, sales force turnover, and company specific headwinds keep him on the sidelines on this name.
10/18/18
WEDB
10/18/18
INITIATION
WEDB
Neutral
Symantec initiated with a Neutral at Wedbush
ZS Zscaler
$44.32

0.32 (0.73%)

10/18/18
WEDB
10/18/18
INITIATION
WEDB
Outperform
Zscaler initiated with an Outperform at Wedbush
10/19/18
WEDB
10/19/18
INITIATION
Target $48
WEDB
Outperform
Zscaler initiated with an Outperform at Wedbush
Wedbush analyst Daniel Ives initiated Zscaler with an Outperform rating and $48 price target, telling investors in a research note that the company is a "disruptive first mover" in cloud security which has essentially created a new market in the cyber security world under an innovative product umbrella and strategic focus disrupting the competitive landscape for years to come. Ives believes Zscaler is one of the best plays in the cloud security arena, which he believes is still in the very early innings of success.
10/19/18
WEDB
10/19/18
NO CHANGE
Target $140
WEDB
Outperform
Wedbush sees cybersecurity spending up 20% y/y in 2019
Wedbush analyst Daniel Ives tells investors in a research note that, based on his initial survey work, he sees cybersecurity spending up 20% y/y in 2019 vs. a 16% increase in 2018, a "very positive" data for the sector. His favorite cybersecurity stocks heading into the end of the year and into 2019 are Check Point (CHKP), Zscaler (ZS), Fortinet (FTNT), Tenable (TENB), Qualys (QLYS) and CyberArt (CYBK), and says overdue M&A could be another positive catalyst for the sector.
12/10/18
GUGG
12/10/18
INITIATION
Target $40
GUGG
Neutral
Zscaler initiated with a Neutral at Guggenheim
Guggenheim analyst Imtiaz Koujalgi started Zscaler with a Neutral rating and $40 price target.
PFPT Proofpoint
$90.28

1.11 (1.24%)

01/08/19
WEDB
01/08/19
NO CHANGE
Target $115
WEDB
Outperform
Proofpoint price target lowered to $115 from $124 at Wedbush
Wedbush analyst Steve Koenig lowered his price target for Proofpoint to $115 from $124, while reiterating an Outperform rating on the shares. His channel checks point to traction with operational adjustments and sales enablement improvements, accelerating cross-selling with Wombat, and continuing competitive differentiation. Also, the security demand environment continues to be solid, providing the basis for good Q4 achievement and more consistent execution in FY19, he adds. Based on the tone of his checks, Koenig's "educated guess" is that Proofpoint met its Q4 internal targets soundly. Although Q1 billings seasonality is expected to be light, the analyst expects acceleration in revenue and billings as FY19 progresses, and is enthusiastic about the opportunity for investors at the current valuation.
12/10/18
GUGG
12/10/18
INITIATION
Target $110
GUGG
Buy
Proofpoint initiated with a Buy at Guggenheim
Guggenheim analyst Imtiaz Koujalgi started Proofpoint with a Buy rating and $110 price target.
10/29/18
10/29/18
UPGRADE
Target $120

Overweight
Proofpoint upgraded to Overweight as pullback creates opportunity at KeyBanc
As previously reported, KeyBanc analyst Rob Owens upgraded Proofpoint to Overweight from Sector Weight, with $120 price target. While last week's earnings results and, more importantly, 2019 guidance disappointed the Street, last week's over-reaction in shares has created a compelling opportunity, he contends.
10/29/18
KEYB
10/29/18
UPGRADE
KEYB
Overweight
Proofpoint upgraded to Overweight from Sector Weight at KeyBanc
PANW Palo Alto Networks
$194.08

3.68 (1.93%)

11/30/18
GABE
11/30/18
UPGRADE
GABE
Buy
Palo Alto Networks upgraded to Buy from Hold at Gabelli
Gabelli analyst Hendi Susanto upgraded Palo Alto to Buy citing recent shares weakness. The analyst views current valuation as attractive and remains favorable on Palo Alto's market leadership, technology platform, and competitive security platform.
12/10/18
GUGG
12/10/18
INITIATION
Target $256
GUGG
Buy
Palo Alto Networks initiated with a Buy at Guggenheim
Guggenheim analyst Imtiaz Koujalgi started Palo Alto Networks with a Buy rating and $256 price target.
11/30/18
BMOC
11/30/18
NO CHANGE
Target $205
BMOC
Market Perform
Palo Alto Networks price target lowered to $205 from $260 at BMO Capital
BMO Capital analyst Keith Bachman lowered his price target on Palo Alto Networks to $205 and kept his Market Perform rating, saying that while the company beat on Q1 earnings, its billings were in line, "which is a downtick from the outperformance in prior quarters". The analyst believes that the free cash flow multiple on Palo Alto Networks is "reasonable", but also warns about the overhang on the stock lingering because of the potential for M&A. Bachman adds that he is concerned by the "durability" of the company's billings growth, adding that his price target reduction reflects "lower free cash flow estimates and a lower multiple due to a reduced equity risk environment".
11/30/18
MAXM
11/30/18
NO CHANGE
Target $280
MAXM
Buy
Palo Alto Networks price target raised to $280 from $274 at Maxim
Maxim analyst Nehal Chokshi raised his price target on Palo Alto Networks to $280 and kept his Buy rating after "another beat and raise quarter", saying the company's strong results were driven by sequential subscription revenue growth. The analyst adds that the above-consensus guidance was the factor of the "uniqueness" of the company's Application Framework. Chokshi is also positive on Palo Alto Networks' CEO plan to extend its business "from security to the intersection of security and AI".

TODAY'S FREE FLY STORIES

ETFC

E-Trade

$47.45

0.88 (1.89%)

17:33
02/17/19
02/17
17:33
02/17/19
17:33
Conference/Events
E-Trade to hold Education Day »

Education Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

PFE

Pfizer

$42.41

0.45 (1.07%)

12:56
02/17/19
02/17
12:56
02/17/19
12:56
Hot Stocks
Pfizer, EMD Serono announce publication of Phase 3 data for BAVENCIO plus INLYTA »

Merck KGaA, which…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 18

    May

MRK

Merck

$79.84

0.9 (1.14%)

, PFE

Pfizer

$42.41

0.45 (1.07%)

12:48
02/17/19
02/17
12:48
02/17/19
12:48
Hot Stocks
Merck presents results from Phase 3 KEYNOTE-426 study »

Merck (MRK) announced…

MRK

Merck

$79.84

0.9 (1.14%)

PFE

Pfizer

$42.41

0.45 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 11

    Apr

  • 18

    May

AVEO

Aveo Pharmaceuticals

$0.62

0.0092 (1.51%)

12:42
02/17/19
02/17
12:42
02/17/19
12:42
Hot Stocks
Aveo Pharmaceuticals presents TIVO-3 trial topline results »

Aveo Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARDM

Aradigm

$0.00

(0.00%)

12:34
02/17/19
02/17
12:34
02/17/19
12:34
Hot Stocks
Aradigm announces plans for reorganization under Chapter 11 »

Aradigm has filed for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

, XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

13:26
02/16/19
02/16
13:26
02/16/19
13:26
Periodicals
Amazon a risk for almost every stock/sector, Barron's says »

Amazon (AMZN) is eating…

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

KR

Kroger

$29.50

0.54 (1.86%)

FAST

Fastenal

$62.97

0.61 (0.98%)

GWW

Grainger

$316.63

4.9 (1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 03

    Mar

  • 18

    Mar

YETI

Yeti

$22.85

0.97 (4.43%)

13:20
02/16/19
02/16
13:20
02/16/19
13:20
Periodicals
Yeti stock has 60% upside, Barron's says »

Yeti Holdings stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

L

Loews

$46.67

0.785 (1.71%)

13:14
02/16/19
02/16
13:14
02/16/19
13:14
Periodicals
Investors can love Loews, Barron's says »

Loews is a $15B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 28

    May

EQIX

Equinix

$421.53

1.16 (0.28%)

, COR

CoreSite Realty

$102.69

0.625 (0.61%)

13:10
02/16/19
02/16
13:10
02/16/19
13:10
Periodicals
Equinix, CoreSite Realty among stocks to play data-center boom, Barron's says »

Data-center stocks may…

EQIX

Equinix

$421.53

1.16 (0.28%)

COR

CoreSite Realty

$102.69

0.625 (0.61%)

IRM

Iron Mountain

$35.13

-0.14 (-0.40%)

INXN

Interxion

$64.65

0.81 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 26

    Mar

  • 26

    Mar

NOK

Nokia

$6.31

0.015 (0.24%)

, ERIC

Ericsson

$9.36

0.015 (0.16%)

13:07
02/16/19
02/16
13:07
02/16/19
13:07
Periodicals
A U.S. ban of Huawei may benefit Ericsson, Samsung, Barron's says »

The next salvo in the…

NOK

Nokia

$6.31

0.015 (0.24%)

ERIC

Ericsson

$9.36

0.015 (0.16%)

SSNLF

Samsung

$0.00

(0.00%)

CSCO

Cisco

$49.45

1.05 (2.17%)

JNPR

Juniper

$27.12

0.16 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

COP

ConocoPhillips

$70.13

1.04 (1.51%)

, MUR

Murphy Oil

$29.23

0.59 (2.06%)

13:00
02/16/19
02/16
13:00
02/16/19
13:00
Periodicals
Dividend investors should look to oil stocks for big yields, Barron's says »

Energy stocks aren't…

COP

ConocoPhillips

$70.13

1.04 (1.51%)

MUR

Murphy Oil

$29.23

0.59 (2.06%)

CVX

Chevron

$119.30

1.19 (1.01%)

VLO

Valero

$84.34

0.75 (0.90%)

XOM

Exxon Mobil

$77.74

1.47 (1.93%)

MRO

Marathon Oil

$17.07

0.15 (0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

  • 07

    Mar

  • 18

    Mar

  • 22

    May

  • 28

    May

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

12:45
02/16/19
02/16
12:45
02/16/19
12:45
Periodicals
Protestors against NY's Amazon HQ2 got math wrong, Barron's says »

On Thursday, Amazon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 20

    Feb

  • 20

    Feb

  • 03

    Mar

  • 18

    Mar

ICE

IntercontinentalExchange

$75.49

-0.46 (-0.61%)

, NDAQ

Nasdaq

$87.74

0.56 (0.64%)

12:28
02/16/19
02/16
12:28
02/16/19
12:28
Periodicals
Investors interested in U.S. cannabis companies face challenges, Barron's says »

Investors interested in…

ICE

IntercontinentalExchange

$75.49

-0.46 (-0.61%)

NDAQ

Nasdaq

$87.74

0.56 (0.64%)

CGC

Canopy Growth

$47.54

1.49 (3.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 28

    May

  • 15

    Feb

AMD

AMD

$23.68

0.55 (2.38%)

, INTC

Intel

$51.64

0.85 (1.67%)

08:43
02/16/19
02/16
08:43
02/16/19
08:43
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMD

AMD

$23.68

0.55 (2.38%)

INTC

Intel

$51.64

0.85 (1.67%)

MRVL

Marvell

$18.82

-0.37 (-1.93%)

MCHP

Microchip

$91.10

0.49 (0.54%)

MU

Micron

$41.99

-0.23 (-0.54%)

NVDA

Nvidia

$157.22

2.69 (1.74%)

QCOM

Qualcomm

$51.97

0.42 (0.81%)

TXN

Texas Instruments

$107.55

0.57 (0.53%)

TWTR

Twitter

$31.23

0.28 (0.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

  • 25

    Feb

  • 07

    Mar

  • 07

    Mar

  • 25

    Mar

  • 26

    Mar

  • 28

    May

  • 04

    Jun

  • 05

    Jun

AMGN

Amgen

$188.31

1.6 (0.86%)

, ALPMY

Astellas Pharma

$0.00

(0.00%)

04:55
02/16/19
02/16
04:55
02/16/19
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2019 ASCO Genitourinary…

AMGN

Amgen

$188.31

1.6 (0.86%)

ALPMY

Astellas Pharma

$0.00

(0.00%)

AZN

AstraZeneca

$40.92

0.93 (2.33%)

BAYRY

Bayer

$0.00

(0.00%)

BMY

Bristol-Myers

$51.64

0.81 (1.59%)

CALA

Calithera Biosciences

$5.35

0.14 (2.69%)

CLVS

Clovis

$25.44

(0.00%)

DNA

Bought by RHHBY

$0.00

(0.00%)

ESALY

Eisai

$0.00

(0.00%)

EXEL

Exelixis

$22.26

-0.05 (-0.22%)

IMMU

Immunomedics

$14.23

0.225 (1.61%)

INO

Inovio

$3.70

0.01 (0.27%)

MRK

Merck

$79.84

0.9 (1.14%)

MYOV

Myovant Sciences

$21.48

0.1 (0.47%)

MYGN

Myriad Genetics

$31.41

0.53 (1.72%)

NH

NantHealth

$0.60

(0.00%)

NVS

Novartis

$89.89

0.865 (0.97%)

PFE

Pfizer

$42.41

0.45 (1.07%)

PGNX

Progenics

$4.87

0.13 (2.74%)

SGEN

Seattle Genetics

$71.48

2.92 (4.26%)

SNY

Sanofi

$42.51

0.94 (2.26%)

TYME

Tyme Technologies

$3.19

0.055 (1.76%)

AVEO

Aveo Pharmaceuticals

$0.62

0.0092 (1.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 16

    Feb

  • 19

    Feb

  • 20

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 07

    Mar

  • 11

    Mar

  • 22

    Mar

  • 11

    Apr

  • 28

    Apr

  • 18

    May

  • 20

    May

WES

Western Gas Partners

$49.52

0.38 (0.77%)

, WGP

Western Gas Equity

$32.38

0.2 (0.62%)

19:30
02/15/19
02/15
19:30
02/15/19
19:30
Recommendations
Western Gas Partners, Western Gas Equity analyst commentary at MUFG »

MUFG raises price targets…

WES

Western Gas Partners

$49.52

0.38 (0.77%)

WGP

Western Gas Equity

$32.38

0.2 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 15

    Feb

  • 04

    Mar

PXD

Pioneer Natural

$145.33

2.27 (1.59%)

19:19
02/15/19
02/15
19:19
02/15/19
19:19
Recommendations
Pioneer Natural analyst commentary at MUFG »

Pioneer Natural price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

ZTS

Zoetis

$95.38

2.16 (2.32%)

18:42
02/15/19
02/15
18:42
02/15/19
18:42
Hot Stocks
Zoetis CEO says: 'Diagnostics are more important in animals than humans' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$136.40

2.13 (1.59%)

18:22
02/15/19
02/15
18:22
02/15/19
18:22
Hot Stocks
Johnson & Johnson CEO: 'We ended 2018 with great results' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 25

    Feb

  • 25

    Feb

  • 06

    Mar

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

18:18
02/15/19
02/15
18:18
02/15/19
18:18
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

BHVN

Biohaven Pharmaceutical

$45.32

1.36 (3.09%)

18:14
02/15/19
02/15
18:14
02/15/19
18:14
Hot Stocks
Biohaven treatment of multiple system atrophy granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$188.31

1.6 (0.86%)

18:11
02/15/19
02/15
18:11
02/15/19
18:11
Hot Stocks
Amgen treatment of Acute Myeloid Leukemia granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$100.19

1.19 (1.20%)

18:02
02/15/19
02/15
18:02
02/15/19
18:02
Hot Stocks
Celanese announces Acetyl Intermediates price increases in China »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

17:58
02/15/19
02/15
17:58
02/15/19
17:58
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

GLD

SPDR Gold Shares

$124.81

0.77 (0.62%)

17:41
02/15/19
02/15
17:41
02/15/19
17:41
Hot Stocks
SPDR Gold Shares holdings fall to 793.03MT from 796.85MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.